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DAX-1 (Dosage-sensitive sex reversal - Adrenal hypoplasia congenita critical region on the X
chromosome 1, ofﬁcially known as NR0B1) and steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) are two
transcription factors that belong to the nuclear receptor superfamily. Both DAX-1 and SF-1 are
expressed in the adrenal gland and reproductive axis during fetal development and in adult life, and
variations in genes encoding these factors are associated with an ever expanding range of adrenal and
reproductive conditions.
In this review, we will provide a brief overview of the history and basic biology of DAX-1 and SF-1
and describe the range of clinical conditions associated with them.Wewill also provide some guidance
on key issues related to management and support for families and children with DAX-1 and SF-1-
associated conditions.
DAX-1 (NR0B1)
History of DAX-1
Adrenal hypoplasia is a life-threatening condition that results from underdevelopment (hypoplasia)
or lack (agenesis) of the adrenal gland. This conditionwas ﬁrst described by the pathologist Sikl in 1948
in a boy with “coal-black pigmentation”who died of a salt-losing adrenal crisis in the ﬁrst weeks of life
[1]. In the 1960s, an X-linked inheritance pattern became clear and, as boys survived following the use
of steroid replacement treatment, it emerged that hypogonadotropic hypogonadism (HH) was an in-
tegral part of this condition. However, it was the association of X-linked adrenal hypoplasia congenita
(AHC) with glycerol kinase deﬁciency (GKD) and Duchenne muscular dystrophy (DMD) that helped to
localise the gene to the short arm of the X-chromosome (Xp21) and speciﬁc changes (mutations) or
deletions of DAX-1 (NR0B1) as the cause of X-linked AHC were ﬁrst described in 1994 [2]. Of note,
duplication of this region was associated with 46,XY DSD/testicular dysgenesis, suggesting that over-
expression of DAX-1 might suppress male sex development pathways and that DAX-1 could act as an
“anti-testis” gene [3].
Biological role of DAX-1
DAX-1 is termed an “orphan” nuclear receptor, as no speciﬁc ligand has been identiﬁed. DAX-1 has
an unusual structure; the carboxyl-terminal region of the protein contains twelve helices typical of
other nuclear receptors, whereas the amino-terminal region contains 3.5 repeats of approximately
66e67 amino acids containing LXXLL motifs (Fig. 1) [4]. Early studies of DAX-1 function suggested it
could interact with other nuclear receptors such as SF-1, and this has been conﬁrmed following
crystallization of DAX-1 with LRH-1 (NR5A2) [5]. Paradoxically, however, most functional studies have
shown that DAX-1 is a repressor of gene transcription, which is unexpected given its positive role in
adrenal and reproductive development, and the fact that loss of DAX-1 is associated with adrenal and
reproduction dysfunction [6].
The exact biological role of DAX-1 remains unclear. Targeted deletion of exon 2 of Dax1 (Nr0b1, also
known as Ahch) using a cre-loxP strategy in mice resulted in animals that had disrupted spermato-
genesis, but apparently normal adrenal function [7]. Breeding these mice onto different backgrounds
disrupted testis development, as did overexpression of Dax1/Nr0b1 on a mouse background with
weaker Sry expression. These studies supported a dosage sensitive role for Dax1 in testis development,
but shed little light onto the lack of adrenal phenotype.
More recently, detailed analysis of adrenal function in aging Dax1/Nr0b1 deleted mice has shown
that adrenal insufﬁciency does develop with time, after an initial period of enhanced hormonal
sensitivity [8]. In fact, it is emerging that DAX-1 may play a key role in regulating stem cell develop-
ment. DAX-1 is expressed in a population of progenitor stem cells where it represses differentiation so
that expansion of the cell pool can occur. In the absence of DAX-1 (and together with tropic signals such
as adrenocorticotropic hormone [ACTH]), the progenitor cells may differentiate into steroidogenic cells
prematurely before expansion of cell number occurs [8,9]. This phenomenon may provide one model
Fig. 1. Cartoon of DAX-1 structure and a selection of the nonsense (stars), frameshift (triangles) and missense changes reported.
Those changes associated with a milder phenotype (red) or isolated mineralcorticoid deﬁciency (yellow) are indicated. LBD ¼ ligand
binding domain. (Modiﬁed with permission from Lin et al., J Clin Endocrinol Metab 2006; 91: 3048e3054. Copyright © 2006 by The
Endocrine Society).
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of cells available for regeneration is depleted.
In addition to the stem cell model, several studies have shown a positive activating role for DAX-1 in
gene transcription rather than repressor role. Studies of the minimal promoter of CYP11B2 showed that
DAX-1 can activate transcription, and augmentation of SF-1 activation was also shown on the PBX1
promoter in adrenal cells [10]. Furthermore, DAX-1 co-activation with the steroid receptor RNA acti-
vator (SRA) has been described [11]. These reports increase the range of potential actions of DAX-1 in
different biological systems.
Clinical conditions associated with alterations in DAX-1
Classic X-linked adrenal hypoplasia congenita
Classic X-linked AHC includes the triad of: a) primary adrenal insufﬁciency (PAI), b) hypogonado-
tropic hypogonadism (HH), and c) impaired fertility.
The adrenal insufﬁciency presents during the ﬁrst two months of life in approximately 40% of
affected boys, or else more insidiously throughout childhood [12]. Typically, boys present with a salt-
losing adrenal crisis due to mineralocorticoid (aldosterone) insufﬁciency, together with glucocorticoid
(cortisol) insufﬁciency. A basal cortisol value within the normal range does not exclude the diagnosis;
however, the response to ACTH-analogue stimulation will usually be impaired.
Boys with X-linked AHC typically have absent pubertal development [13]. This feature is consistent
with HH, although puberty may start in some boys and usually arrests around Prader stage 3. Detailed
studies of gonadotropin release and the response to pulsed gonadotropin-releasing hormone (GnRH)
stimulation have suggested that a combined hypothalamic and pituitary defect occurs, which is
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general, studies using pulsatile GnRH delivered through pump systems have not been very successful
in inducing puberty.
Following studies in the mouse, it has become apparent that disruption of DAX-1/NR0B1 may also
cause a primary defect in spermatogenesis. The Dax1/Nr0b1 deleted mouse has altered testicular ar-
chitecture and spermatogenesis [7]. Attempts to induce spermatogenesis in patients using FSH and
human chorionic gonadotropin (hCG) have generally been disappointing [14]. However, data from
humans about the exact mechanism and natural history of impaired spermatogenesis are currently
limited (see management).
Other presentations in childhood
Although most boys present with PAI and classic features of X-linked AHC, alternative presenting
phenotypes have emerged. These may include a predominant mineralocorticoid insufﬁciency and salt-
loss, resembling other conditions such as aldosterone synthase deﬁciency or pseudohypoaldosteron-
ism [15,16]. Rarely, patients may present with low cortisol, and are thought to have familial gluco-
corticoid deﬁciency. Therefore, an openmind needs to be kept in all boys with adrenal insufﬁciency if a
speciﬁc molecular diagnosis has not been reached, especially if other features such as HH emerge or
there is a family history consistent with X-linked inheritance.
In general, the adrenal features of X-linked AHC precede the reproductive features and it is rare for
young adults to present with impaired puberty without some history or undiagnosed features of PAI.
Indeed, a study of more than 100 subjects with HH or familial extreme delayed puberty did not reveal
any pathogenic DAX-1/NR0B1 variants [17]. In contrast, a subgroup of boys with X-liked AHC may
present with signs of increased hypothalamo-gonadotrope activation or early puberty. For example,
boys may have an enlarged penis (macrophallia) at birth, or a degree of premature sexual maturation
(precocious puberty) in early childhood [16,18]. Signs of puberty may occur before or after the diag-
nosis of adrenal insufﬁciency, and it is not entirely clear whether this is gonadotropin dependent or
independent. Usually the sexual development arrests relatively early on.
Another presenting feature of X-liked AHC can be the metabolic or phenotypic features of GKD or
neuromuscular effects of DMD, although most boys with a contiguous gene deletion develop adrenal
dysfunction early.
Late-onset X-linked AHC
Occasionally, X-linked AHC is ﬁrst diagnosed in young adulthood. Affected men typically have a
history or features of a progressive or mild adrenal insufﬁciency and partial HH is diagnosed on further
examination [19,20]. Rarely, a young man who presents with impaired puberty or arrested sexual
development is found to have clinical or biochemical evidence of PAI, leading to the diagnosis of X-
linked AHC [21]. Therefore, any history of fatigue, weight loss, exaggerated illness or hyperpigmen-
tation should not be ignored. Brothers or maternal uncles can be affected, so a careful family history
and investigations may be needed [22,23]. To date, a diagnosis of X-linked AHC has never beenmade in
men being investigated for male factor infertility alone [24].
Presentation in females
Although X-linked AHC predominantly affects boys, expression of X-linked conditions can some-
times occur in girls or women due to skewed X-inactivation. This mechanism has been proposed for the
delayed puberty seen in female family members in a kindred where boys have classic X-linked adrenal
hyperplasia and for the mild DMD and adrenal insufﬁciency in a girl caused by a contiguous gene
deletion of Xp21 [13,25].
Presymptomatic diagnosis
Once a diagnosis of X-linked AHC is made it is important to consider who else in the family might be
at risk of developing adrenal insufﬁciency or who might carry the genetic alteration and pass it on.
Analysis of sibling (brother) pairs with X-linked AHC has shown that the second child tends to be
diagnosed at a younger age, probably due to increased awareness of the signs of adrenal insufﬁciency
[26]. Making a presymptomatic diagnosis is an important aim as it prevents a life-threatening salt-
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emergency [26]. Sisters and maternal aunts should be offered genetic testing as they are potential
heterozygous carriers and can have affected sons [22,23].
The genetic basis of X-linked AHC
The gene encoding DAX-1 is ofﬁcially termed NR0B1.
The gene consists of just two exons with a potential alternatively spliced exon 2, although the
signiﬁcance of this remains unclear.
As highlighted above, X-linked AHC was originally characterized as part of a contiguous gene
deletion syndrome together with GKD and DMD (centromeric) or developmental delay (IL1RAPL1,
telomeric). In a review of X-linked AHC in 2006, contiguous gene deletions accounted for 71 of 190
(38%) published cases at the time, probably reﬂecting a reporting bias [27]. Since then, isolated de-
letions of NR0B1 and speciﬁc point changes (mutations) within DAX-1/NR0B1 itself seem much more
prevalent (Fig. 1) [27]. Very rarely, X-linked AHC can arise from rearrangements of the genetic locus for
NR0B1 or from disruption of upstream regulatory regions.
Speciﬁc disease-causing variants in DAX-1/NR0B1 include nonsense mutations, frameshift muta-
tions and point (missense) mutations (Fig. 1). Nonsense mutations are located throughout the gene/
protein and loss of the very carboxyl-terminal region of the protein that contributes to the AF-2 domain
is associated with a severe phenotype and loss of function in cell based transcription assays [6,28]. Of
note, nonsense changes in the amino-terminal region can be found in patients with late-onset AHC,
especially affecting codons 37 and 39 in the ﬁrst repeat region of DAX-1 [20,22,23]. It has been sug-
gested that alternative in-frame translation from a methionine at codon 83 generates a protein lacking
an amino-terminal motif but with sufﬁcient function to partially “rescue” the phenotype, resulting in
delayed onset of symptoms [20].
Frameshift mutations in DAX-1/NR0B1 are generally highly disruptive and are located throughout
the gene and protein. In contrast, missense changes (disease causing single nucleotide variants) are
clustered within certain key regions of the putative ligand binding region of DAX-1, with several amino
acid “hotspots” showing multiple changes (e.g. p.L262, p.W291, p.A300, p.E377, p.L381, p.R425) [28,29]
(Fig. 1, lower panel). These amino acids often associate with the hydrophobic core of the protein and
may play a role in protein stability as well as nuclear localization. Several speciﬁc changes in these
regions have been associated with a milder or late-onset phenotype (e.g., p.I439S, p.Y380D) [19,21].
These changes have partial function in different gene transcription assays, in keeping with the milder
clinical phenotype. Variants within the amino-terminal repeat regions of DAX-1 are very rare (e.g.
p.C200W) and the signiﬁcance of these in individuals with X-linked AHC is less clear [30].
Management of X-linked adrenal hypoplasia
Infants and childrenwho present with acute adrenal insufﬁciency require appropriatemanagement
with resuscitation, ﬂuid replacement and intravenous hydrocortisone treatment accordingly to stan-
dard guidelines. Careful attention to blood pressure, hypoglycaemia, electrolyte disturbances (hypo-
natraemia, hyperkalaemia) and any precipitating factors (e.g. sepsis) is needed. Replacement doses of
hydrocortisone and ﬂudrocortisone can be introduced once the child is stable, and salt supplements are
needed for around the ﬁrst 12e18 months of life in those boys who present in early infancy. Education
andmonitoring are neededwith an awareness of when to increase steroid doses during illness or stress
and when to administer emergency hydrocortisone injections. Medical alert systems should be worn
and schools and emergency services should be familiar about dealing with acute problems. Easy access
to hospital should be available. Alternative steroid replacement regimen may be tried in later life but it
is best to avoid long acting steroids such as dexamethasone. Newer slow release preparations of hy-
drocortisone are becoming available.
Early investigations are needed at the time of presentation to conﬁrm PAI and to establish a
diagnosis of X-linked AHC in contrast to other causes of adrenal insufﬁciency. The differential diagnosis
can vary with age. Typically, an inappropriately low cortisol (for the clinical situation), elevated ACTH,
hyponatraemia, hyperkalaemia, low aldosterone and increased plasma renin activity (for age-adjusted
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is a useful assessment of adrenal reserve, though it is not always easy to perform this test if there is an
acute presentation. Alternative diagnoses should be excluded such as congenital adrenal hyperplasia
(most commonly 21-hydroxylase deﬁciency) and metabolic causes in the newborn period and auto-
immune, metabolic (e.g. X-linked adrenoleukodystrophy) and other causes in childhood. Additional
tests such as urine steroid proﬁling, measurement of 17-hydroxyprogesterone (17-OHP), very-long
chain fatty acids (VLCFAs) and autoantibodies can be useful, and a detailed consideration of the
many causes of PAI is needed. A family history of adrenal insufﬁciency in boys (or unexplained death)
can be useful, although around 40% of male infants with salt-losing adrenal insufﬁciency and no family
history or clear cause have X-linked AHC due to mutations in DAX-1/NR0B1 [27]. Genetic testing is
invaluable to identify speciﬁc mutations in DAX-1/NR0B1 and to conﬁrm the diagnosis of X-linked AHC.
Measurement of creatine kinase and urinary glycerol is needed where a contiguous gene deletion
syndrome is possible.
Most boys with X-linked AHC do not progress through puberty and need sex hormone replacement.
Several attempts have been made to induce puberty using GnRH pumps but these have been generally
unsuccessful suggesting a combined pituitary as well as hypothalamic defect [13]. Repeated injections
of hCG often stimulate testosterone production but in practice it is generally easier to use standard
preparations of testosterone to induce puberty and for maintenance sex-hormone replacement
throughout adulthood.
Exogenous FSH together with hCG has been tried in an attempt to induce spermatogenesis in young
menwith X-linked AHC. Generally these approaches have been unsuccessful alone. However, the use of
testicular sperm extraction (TESE) coupled with intracytoplasmic sperm injection (ISCI) has been re-
ported to result in a successful pregnancy and live birth in a manwith classic early onset X-linked AHC,
who had received repeated courses of FSH/hCG stimulation previously [31]. This case brings hope to
menwith his condition, although more data are needed to know how successful this approach will be.
Information and support
Children and families with adrenal insufﬁciency need education and support from their local
hospital and training in emergency measures and dealing with sickness (an example is at http://www.
gosh.nhs.uk/medical-information/medicines-information/emergency-pack-children-cortisol-
deﬁciency). Adrenal insufﬁciency support groups (sometimes termed “Addison's”) can be very helpful
(http://www.addisons.org.uk; http://www.nadf.us) although often they are more focussed on adults.
Psychological support may be needed to help the boys deal with puberty and fertility issues. Infor-
mation about X-linked AHC is available at GeneReviews (http://www.ncbi.nlm.nih.gov/books/
NBK1431/).
Steroidogenic factor-1 (SF-1, NR5A1, Ad4BP)
History of SF-1
Steroidogenic factor-1 (SF-1, ofﬁcially termed NR5A1) was ﬁrst identiﬁed in the early 1990s
following the work of Keith Parker (USA) and Ken-ichirou Morohashi (Japan). Both groups postulated
that a common master regulator of steroidogenesis exists [32,33]. Using different experimental ap-
proaches they identiﬁed a nuclear receptor that could regulate the promoters of steroidogenic genes
in vitro. The key role for SF-1 in adrenal and reproductive development was conﬁrmed following the
generation of the Sf-1 knockout mouse model [34].
Biological role of SF-1
SF-1 is a member of the nuclear receptor superfamily. The amino-terminal region of SF-1 contains a
classic two zinc ﬁnger DNA-binding domain, whereas the carboxyl-terminal region of SF-1 has a 12
helix structure similar to that found in nuclear receptors. SF-1 belongs to a small group of nuclear
receptors that are believed to bind to DNA as a monomer, recognizing variations on a PyCA AGGTCA
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interactions with other transcription factor partners may also be important.
SF-1 has an unusual “hinge” region between the main domains and may undergo various forms of
post-translational modiﬁcation such as phosphorylation (activation) and sumoylation [36,37]. SF-1
may also interact with DAX-1 directly to regulate gene transcription. SF-1 was originally termed an
“orphan” nuclear receptor as no high afﬁnity ligand was known. Following the crystallization of the SF-
1 ligand binding region it was suggested that phospholipids can bind to SF-1 and regulate its function,
possibly mediating the downstream effects of certain signalling pathways or interfering with DAX-1
repression [38].
SF-1 was originally shown to activate the promoters of many key genes involved in steroidogenesis,
adrenal development and reproduction in relatively simple in vitro assays. However, strong in vivo
evidence for the role of SF-1 in these systems came following the generation of the Sf-1 (Ftz-F1, Nr5a1)
mouse model [34]. Targeted deletion of Nr5a1 caused adrenal agenesis, gonadal (testicular) dysgenesis
with a subsequent female phenotype and persistence of Müllerian structures (uterus) in XY animals,
altered structure of the ventromedial hypothalamus (VMH), variable degrees of HH, and hyposplenism
[34,39]. Late-onset obesity due to altered central regulation of energy expenditure may be a long-term
feature [40]. Haploinsufﬁcient animals have a disordered adrenal architecture and reduced gonad
weight, whereas altered ovarian reserve is seen in tissue-speciﬁc granulosa cell deletion of Nr5a1 in
females [41,42]. These biological models are providing new insights into the in vivo effects of Sf-1 in
different systems, including the brain.
Other approaches have been used to try to identify novel SF-1 targets, using hypothesis generating
approaches rather than focussing on the promoters of likely candidate genes. Using a ChIP-on-CHIP
approach, we have identiﬁed a potential role for SF-1 in regulating angiogenesis in the developing
adrenal gland through remodelling by angiopoietin-2 (ANGPT2). In addition, bidirectional manipula-
tion of SF-1 in adrenal cells followed by microarray analysis was used to show that SF-1 can positively
regulate sterol-O-acyl transferase (SOAT1, ACAT1), an important adrenal mediator of cholesterol
biosynthesis and possible target for treatment of adrenal cancer [43,44]. Other data following ChIP-Seq
approaches to identify SF-1 targets are emerging [45,46].
Clinical conditions associated with alterations in SF-1
Gonadal (testicular) dysgenesis and adrenal insufﬁciency
Initial attempts to ﬁnd disease causing variations (mutations) in SF-1/NR5A1 focussed on in-
dividuals with a phenotype similar to themousemodel of complete gonadal dysgenesis with persistent
Müllerian structures and primary adrenal failure. This is a rare phenotype in humans, but a girl (46,XY),
who had these features, was found to have a de novo heterozygous (dominant) mutation in SF-1/NR5A1
in 1999 [47]. The alteration (p.G35E) affects a key amino acid in the “P”-box of the ﬁrst zinc ﬁnger of SF-
1, a region crucial for recognizing DNA-binding motives of target genes (Fig. 2) [35]. This change was
seen to be competitive in most assays but may have some dominant negative activity with certain
binding complexes.
A second child with a similar phenotype was reported in 2002 [48]. This child came from a
consanguineous family and had a homozygous (recessive) mutation (p.R92Q) affecting a key amino
acid in the “A”-box (within the FtzF1 box) of SF-1 that is involved in supporting monomeric binding
(Fig. 2). This variant caused partial loss of function of SF-1, consistent with the need for the change to be
present in a homozygous state and suggesting the functional gene dosage effects of SF-1 are important
[35,48]. Although a heterozygous variant in SF-1/NR5A1 has been found in a girl (46,XX) with adrenal
insufﬁciency, alterations in SF-1/NR5A1 in patients with an adrenal phenotype are rare [27,49].
46,XY DSD
In contrast to the effect of SF-1 on the adrenal gland, it has emerged in the past decade that het-
erozygous changes in SF-1/NR5A1 are a remarkably frequent (10e20%) cause of 46,XY DSD [50e53].
The most common phenotype is a baby with atypical (ambiguous) genitalia, with or more commonly
without Müllerian structures, and with variable degrees of testicular dysgenesis and impaired
androgen production. Often the testes are relatively well formed and the primary defect appears to be
Fig. 2. Cartoon of SF-1 structure and a selection of the changes reported in patients with adrenal insufﬁciency and/or reproductive
phenotypes. Nonsense (stars), frameshift (triangles) and missense changes are indicated. Those associated with 46,XX primary
ovarian insufﬁciency are shown in the upper panel and those in 46,XY phenotypes are shown in the lower panel. (Modiﬁed with
permission from Lin et al., J Clin Endocrinol Metab 2006; 91: 3048e3054. Copyright © 2006 by The Endocrine Society).
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newborn period and a baby is misdiagnosed as having partial androgen insensitivity syndrome [54,55].
Furthermore, several girls with SF-1/NR5A1mutations have ﬁrst presented with progressive androgen
production and virilisation in adolescence, mimicking 5 alpha-reductase deﬁciency or 17 beta-
hydroxysteroid dehydrogenase deﬁciency [56,57]. Hyposplenism has been described in one child
with 46,XY DSD [58].
Hypospadias and undescended testes
Studies of boys with hypospadias have revealed SF-1/NR5A1 mutations in around 5% of those with
penoscrotal hypospadias, a small phallus and at least one undescended testis [59]. SF-1/NR5A1 changes
in boys with less severe forms of hypospadias are less common.
Bilateral anorchia
Analysis of a cohort of boys with bilateral anorchia (vanishing testis syndrome) found a hetero-
zygous SF-1/NR5A1 mutation in one out of 24 children [60]. Although anorchia is often believed to
reﬂect neonatal torsion or a vascular event, a small subgroup of bilateral anorchia may represent
progressive late onset testicular dysgenesis, occurring after the external genitalia have formed.
Male factor infertility
At the mildest end of the spectrum, variations in SF-1/NR5A1 may be responsible for a subset of
male factor infertility [61]. This likely represents 1e3.7% of infertility where chromosomal anomalies
and Y chromosome microdeletions have been excluded [61e63]. Data are limited but some of these
menmay be at risk of a progressive decline in sperm function over time [61]. Furthermore, testosterone
production may be reduced in men with SF-1 associated infertility, so endocrine function needs to be
monitored in these situations.
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Although most focus has been on SF-1 in the testis, ovarian development and function is also
inﬂuenced by SF-1 and POI has been reported in sisters or mothers of children with 46,XY DSD who
were found to carry heterozygous SF-1/NR5A1 changes [64,65]. SF-1 likely has multiple effects on the
ovary, including on stromal development, endocrine function and follicle recruitment and reserve. The
clinical phenotype is very variable; complete early ovarian insufﬁciency and absence of puberty is seen
in rare situations, whereas early menopause and decreased ovarian reserve is more common. Other
womenmay harbour SF-1/NR5A1mutations without any clinical effect on ovarian function, suggesting
that SF-1 effects have variable penetrance. However, SF-1/NR5A1 mutations are relatively rare
(1.4e1.6%) in women with sporadic POI of unknown aetiology [66,67].
Overactivity of SF-1
Overexpression or overactivity of SF-1 may be clinically relevant in certain conditions. Somatic
duplication of the genetic locus encoding SF-1 has been reported in a high proportion of paediatric
adrenal carcinomas, and overexpression of SF-1/NR5A1 has been shown to be present in many adult
adrenal tumours and to be an important predictor of poor outcome [68,69]. Overactivity of SF-1 has
been proposed to be associated with other conditions, such as hyperandrogenic polycystic ovarian
syndrome (PCOS) and endometriosis [70].
The genetic basis of SF-1-associated conditions
The gene encoding SF-1 (NR5A1) is located on the long-arm of chromosome 9 (9q33.3) and consists
of 7 exons (6 coding exons). Variations in SF-1/NR5A1 associated with speciﬁc disease phenotypes are
shown in Fig. 2.
As described above, changes found in individuals with testicular dysgenesis and adrenal insuf-
ﬁciency are rare and tend to be located in critical amino acids for DNA binding, either in heterozy-
gous or homozygous states. Changes associated with 46,XY DSD or hypospadias can be missense
(point), nonsense or frameshift mutations throughout the gene, with point mutations often affecting
the DNA-binding regions. Infertility-associated variants in SF-1/NR5A1 tend to be found more in the
hinge region. A common polymorphism in SF-1/NR5A1 (p.G146A) has been reported to be higher in
some small cohorts with hypospadias or cryptorchidism but this is a common variant in different
ancestral populations and its inﬂuence as a modiﬁer is not known. Haploinsufﬁciency of SF-1/NR5A1
has been detected by techniques such as MLPA in a small number of children with 46,XY DSD and a
contiguous gene deletion syndrome including genitopatellar syndrome has also been described
[71,72].
Most disease-associated variants in SF-1/NR5A1 are heterozygous, with rare homozygous partial
loss of function changes described [48,58,64]. Often these occur de novo and are associated with
infertility so cannot be passed on. However, around 30% of children with 46,XY DSD inherit a het-
erozygous change from their mother in a sex-limited dominant manner [51]. In these kindred there is
a 50% chance of a 46,XY sibling being affected or 46,XX sibling being a carrier, and extended family
members of the mother's side may have 46,XY DSD, hypospadias or infertility. This inheritance
pattern can mimic an X-linked disorder and many of these children have been thought to have partial
androgen insensitivity syndrome [54]. Female carriers are at risk of developing POI and need to be
counselled accordingly. To date, no complete loss of function or deletions of SF-1/NR5A1 have been
described.
Management of SF-1 associated conditions
As the clinical effects of SF-1 are wide and sometimes variable, management plans need to be
tailored to individuals and their families. Those rare children presenting with adrenal insufﬁciency
need resuscitation and adrenal steroid replacement as outlined earlier in the section on X-linked
AHC. Children with various forms of 46,XY DSD should be assessed by a specialist multidisciplinary
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management, with the child's long-term interests as the focus. Key areas to consider are: likely
gender identity; endocrine, urological and sexual function; fertility potential; and tumour risk. A
small number of children with SF-1/NR5A1 mutations have been initially raised female but then
changed to male, though data are very limited. Long term endocrine function and fertility are un-
predictable and need to be monitored. The risk of germ cell tumours is unknown although intra-
tubular germ cell neoplasia has been seen, so retained testes need careful surveillance [56]. Women
and girls at risk of POI need careful monitoring and, if requested, endocrine function and ovarian
reserve can be assessed. It is not known whether ovarian cryopreservation will be useful in main-
taining integrity of the ovary for later retransplantation but this is being considered in several
centres. The long term risks of developing adrenal insufﬁciency or other metabolic effects are un-
known. Adrenal insufﬁciency is not common in those children with being followed up with 46,XY
DSD but long-term studies are needed.Information and support
Families and childrenwith adrenal insufﬁciency need education and support from the local hospital
as outlined for X-linked AHC. Children with 46,XY DSD need evaluation and support from an experi-
enced MDT. Other family support organisations such as dsdfamilies (www.dsdfamilies.org) can be very
helpful and speciﬁc resources for SF-1 are being developed (www.steroidogenicfactor1.info).
Summary
DAX-1 and SF-1 have important roles in human endocrine disorders. Although DAX-1 was iden-
tiﬁed as a cause of X-linked AHC more than 20 years ago, the range of clinical presenting features has
expanded and late-onset forms of the condition are increasingly recognized. X-linked AHC should be
considered in the differential diagnosis of all forms of adrenal insufﬁciency in boys and men, and in
rare situations in girls too. Careful attention to adrenal replacement, puberty development and
fertility is needed. Some hope has emerged that TESE-ISCI might provide an option for assisted
reproduction, but more data are required. The ﬁrst description of SF-1 as a cause of human adrenal
and testicular dysgenesis was published more than 15 years ago, and the spectrum of SF-1 associated
conditions has also expanded rapidly. Adrenal insufﬁciency is only very rarely associated with
disruption of SF-1 whereas a range of reproductive phenotypes are more commonly seen, including
male factor infertility and POI. Long-term outcome studies for all these conditions are needed to
optimize management in the future. Support and education for young people and their families is an
important priority.Practice Points
 X-linked AHC due to DAX-1 (NR0B1) mutations is an important cause of adrenal insufficiency
in boys and specific long-term focus on puberty and fertility is needed
 Late-onset X-linked AHC is being increasingly recognised in the adult clinic
 Genetic analysis can help to identify family members at risk of adrenal insufficiency and
female carriers
 Variations in SF-1/NR5A1 are a common cause of 46,XY DSD and can result in a spectrum of
phenotypes
 Inheritance patterns are variable and genetic analysis can help to identify women or girls who
might be at risk of POI
 Education and support for young people and families is important for both DAX-1 and SF-1-
associated conditions
Research Agenda
 A better understanding of DAX-1 and SF-1 in development and tumorigenesis is needed,
especially in relation to stem cell biology
 The mechanisms of infertility associated with DAX-1 mutations are poorly understood and
more insight into fertility options are needed
 Long-term outcome studies are needed to understand how alterations in SF-1 influence
gender, endocrine function, fertility and tumour risk
 The natural history of POI associated with SF-1 is not well understood and it is not known if
approaches such as ovarian cryopreservation will be useful
 It is not known whether variations in SF-1/NR5A1 and DAX-1/NR0B1 may effect population
health
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